Actively Recruiting
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Led by Centre hospitalier de l'Université de Montréal (CHUM) · Updated on 2026-02-05
440
Participants Needed
4
Research Sites
225 weeks
Total Duration
On this page
Sponsors
C
Centre hospitalier de l'Université de Montréal (CHUM)
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if administering a high dose stimulant with Contingency Management reduces days of use in adults who use methamphetamine better than the usual treatment provided by the clinic. The main questions the trial aims to answer are: Is a high dose stimulant better than a placebo and usual treatment at helping reduce the number of days they use methamphetamine? Is a high dose stimulant with contingency management better than placebo and usual treatment at helping people reduce the number of days they use methamphetamine? Participants will be placed randomly into one of four groups: 1. Usual treatment and placebo 2. Usual treatment, placebo and contingency management 3. Usual treatment and high dose stimulant 4. Usual treatment, high dose stimulant and contingency management Participation includes the following: 1. Participants will receive medication or placebo weekly for 15 weeks. 2. Participants will attend the clinic for weekly treatment 3. Participants will attend the clinic once every 2 weeks for study visits. Each visit will take about an hour to complete. At these visits, participants will be asked to provide a urine sample and complete questionnaires.
CONDITIONS
Official Title
Clinical Trial of High Dose Lisdexamfetamine and Contingency Management in MA Users
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between 18 and 55 years of age
- Diagnosed with moderate to severe methamphetamine use disorder according to DSM-5 criteria
- Active methamphetamine use with self-reported use at least 14 days in the past 28 days verified by urine test
- Interested in reducing or stopping methamphetamine use
- For females: either not able to have children (postmenopausal or surgically sterilized) or of childbearing potential with a negative pregnancy test and willing to use birth control during the study
- Willing to be randomly assigned to one of the four study groups and complete the study
- Able to give informed consent
- Able to follow study procedures
- Able to communicate in English or French
You will not qualify if you...
- Having symptomatic or advanced cardiovascular disease, moderate hypertension, or current hyperthyroidism
- Known allergy or severe reaction to sympathomimetic amines or glaucoma
- Any severe or unstable substance use disorder that would prevent safe participation
- Opioid use disorder patients on opioid agonist therapy for less than 12 weeks or not yet stable
- Current or history of serious psychiatric disorders like bipolar disorder or schizophrenia
- Previous severe allergic reaction to lisdexamfetamine or similar drugs
- Pregnant, nursing, or planning pregnancy during the study
- Planned long absence during the study that may prevent completion
- Use of investigational drugs for stimulant use disorder within 30 days before screening
- Receiving contingency management for stimulant use disorder within 4 weeks before screening
- Use of prescribed amphetamine-type or stimulant disorder medications within 4 weeks before screening
- Need for medications that interact with lisdexamfetamine currently or within the past 14 days
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Rapid Access Addiction Medicine Clinic, St. Paul's Hospital
Vancouver, British Columbia, Canada
Actively Recruiting
2
River Stone Recovery Centre
Fredericton, New Brunswick, Canada, E3B 1E3
Suspended
3
Center for Addiction and Mental Health
Toronto, Ontario, Canada, M6J 1HN
Actively Recruiting
4
University of Montreal Hospital Research Center
Montreal, Quebec, Canada, H2X 0A9
Actively Recruiting
Research Team
D
Devon Blanchette
CONTACT
A
Amina Sow
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here